Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
29.91+0.31 (+1.05%)
At close: 04:00PM EDT
29.91 +0.00 (+0.02%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close29.60
Open29.73
Bid29.00 x 800
Ask35.77 x 900
Day's Range29.49 - 29.92
52 Week Range28.75 - 42.45
Volume357,840
Avg. Volume547,265
Market Cap17.529B
Beta (5Y Monthly)0.94
PE Ratio (TTM)18.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.71 (2.37%)
Ex-Dividend DateMay 13, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
17% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for FMS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fresenius Medical Care AG
    Analyst Report: Fresenius Medical Care AG & Co. KGaAFresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
    Rating
    Fair Value
    Economic Moat
    16 days agoMorningstar
View more
  • Zacks

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.

  • Reuters

    Fresenius warns of bigger Ukraine war impact after Q1 profit beat

    German healthcare group Fresenius's first-quarter profit exceeded market expectations on Wednesday, driven by growth in its generic infusion drugs unit in emerging markets. However, the group warned cost inflation and supply chain disruptions were likely to increase this year, fuelled by Russia's invasion of Ukraine. Fresenius's businesses include the Helios hospital chain, drugmaker Kabi, medical services firm Vamed and dialysis specialist Fresenius Medical Care (FMC).

  • Zacks

    Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care

    Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.

Advertisement
Advertisement